Redhill Gains Most in 7 Months on RHB-102 Clinical Trial Success

Redhill Biopharma Ltd. (RDHL) surged the most in almost seven months after the Israeli pharmaceutical company said a clinical trial of its RHB-102 drug against nausea and vomiting in cancer treatments was successful.

The shares jumped as much as 22 percent, the biggest intraday increase since September 2011, and were 16 percent up at 2.50 shekels as of 10:38 a.m. in Tel Aviv, giving the company a market value of 131 million shekels ($35 million).

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Calev Ben-David at cbendavid@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.